Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


3rd International Conference on Advanced Clinical Research and Clinical Trials

Dublin, Ireland

Shuo Chen

Shuo Chen

Institute of hematology and Blood Diseases Hospital – CAS, China

Title: The possibility of the use of single Institutional Review Board (IRB) for multi-site research in China


Biography: Shuo Chen


With the rapid development of biomedicine in recent years, multi-site research has become the world trend; as a result, there is no other way but to apply for multi-IRB review for the commencement of the trial. The duplicate IRB review by each site increases administrative burdens and cost for sponsors and brings no substantive good to the human subject protection. In October 2016, National Health and Family Planning Commission in China issued Guideline on the IRB review on the biomedical research involving human subjects. It mentions in order to keep the consistency and efficiency of multi-center research, the IRB in each site can establish a collaborative review mechanism, which means the lead site reviews the protocol and rely site reviews its feasibility. In June 2016, the National Institutes of Health (NIH) issued new guidance on single-IRB review of multicenter studies, which brings a new era in multicenter studies